Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Open Orphan Plc ( (GB:HVO) ) has shared an update.
hVIVO plc announced an update regarding its Non-Executive Director, Martin Gouldstone, who is also the CEO of Oncimmune Holdings plc. Oncimmune Holdings has been placed into administration as of March 26, 2025. This development may have implications for hVIVO’s governance and could impact stakeholders’ perceptions of the company’s stability and leadership.
More about Open Orphan Plc
hVIVO plc is a rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human challenge trials. The company provides comprehensive clinical development services to a diverse client base, including major biopharma companies. hVIVO operates a state-of-the-art quarantine facility in London and offers virology and immunology laboratory services. Through its subsidiaries, CRS and Venn Life Sciences, hVIVO offers early-phase clinical trial services and drug development consulting.
YTD Price Performance: -23.41%
Average Trading Volume: 3,109,103
Technical Sentiment Signal: Buy
Current Market Cap: £107.8M
For detailed information about HVO stock, go to TipRanks’ Stock Analysis page.